EUCTR2015-002530-50-ES进行中（未招募）1 期
A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy. - Rim4DMD
EspeRare0 个研究点目标入组 20 人开始时间: 2015年8月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Duchenne muscular dystrophy genetically confirmed;
- •2. Males between 6 and 14 years old;
- •3. Able to walk independently at least 75 meters;
- •4. Patients on a stable dose of corticosteroids at least 6 months prior to baseline;
- •5. Willing and able to comply with all protocol requirements and procedures;
- •6. Signed informed consents by the parent(s)/legal guardian(s);
- •7. France only: Affiliated to or a beneficiary of a social security system
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with significant renal disease or impairment, with Glomerular Filtration Rate estimated using plasma cystatin C level using the Filler formula less than 90ml/min/ 1.73m2;
- •2. Current or history of liver disease or impairment,
- •3. History of any significant medical disorder which may confound the interpretation of either efficacy or safety data e.g. inflammatory, coagulation disease, unstable cardiac or respiratory disease;
- •4. Acute illness within 4 weeks of the first administration of study medication which may interfere with study assessments;
- •5. Significant change of dosage and/or dosing regimens for corticosteroids planned for the duration of study medication;
- •6. Use of beta blockers / and ACEI or ARB unless at stable dose for at least 3 months prior to baseline;
- •7. Use of protocol pump inhibitors unless at a stable dose for at least 3 months prior to baseline
- •8. Use of aldosterone antagonists (i.e. spironolactone, eplerenone) within 3 months prior to first administration of study medication;
- •9. Use of anticoagulants, antithrombotics or antiplatelet agents,
- •10. Previous treatment with idebenone or other forms of Coenzyme Q10 within 1 month of the first administration of study medication;
- •11. Previous treatment with investigational drugs within 4 weeks (or 7 half-life if longer than 4 weeks) of the first administration of study medication including placebo;
- •12. A baseline QTc>450msec,or history of risk factors for torsades de pointes (eg, heart failure, hypokalaemia, family history of long QT syndrome);
- •13. LVEF = 45% at screening or within the past 6 months and/or history of acute heart failure;
- •14. Ventilator dependent;
- •15. Known individual hypersensitivity to any of the ingredients/excipients of the study medication;
- •16. For patients willing to undergo MRI/MRS assessments: Patients with specific contraindication to MRI (e.g.: metallic foreign body, claustrophobia, etc.).
研究者
相似试验
进行中（未招募）
1 期
A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of rimeporide in patients with Duchenne Muscular Dystrophy (DMD)Distrofia Muscolare di Duchenne (DMD)MedDRA version: 20.0 Level: PT Classification code 10013801 Term: Duchenne muscular dystrophy System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-002530-50-ITESPERARE FOUNDATIO20
进行中（未招募）
1 期
Rimeporide in patients with Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)MedDRA version: 18.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-002530-50-GBEspeRare20
进行中（未招募）
1 期
Rimeporide in patients with Duchenne Muscular DystrophyEUCTR2015-002530-50-FREspeRare20
已完成
1 期
A study to evaluate the safety, tolerability, processing by the body, and response of the body to the drug RO7497987 in single and multiple ascending doses in healthy volunteersISRCTN92655801Roche (United States)60
已完成
不适用
An open-label phase 1b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma.Pancreatic cancerNL-OMON42021Chemocentryx29